Verbatim response from ChatGPT
Short answer
- On GLP‑1 or GLP‑1/GIP drugs people typically lose measurable weight within weeks and on average lose roughly 10–20% of body weight over 6–18 months in clinical trials. Semaglutide (Wegovy) trials averaged ~15% at ~68 weeks; tirzepatide (Zepbound/Mounjaro) trials showed larger mean losses (up to ~20% at ~72 weeks) on the higher doses. Individual results vary a lot.
How fast you can expect to lose weight
- Early: appetite drops and you can see weight loss within 2–4 weeks (often faster in the first 3–6 months).
- Typical clinical-trial pattern: faster loss in months 1–6, then slower continued loss or a plateau through 12–18 months.
- Average amounts: roughly 0.5–1.5% of body weight per month early on, summing to ~10–20% after one year in many trial populations. Some people lose more quickly; some much less.
Why results vary
- Dose and drug: higher-dose semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro) generally produce bigger loss than lower-dose GLP‑1s used for diabetes (e.g., Ozempic at diabetes doses).
- Starting weight, biology, insulin/resistance, hormones, other meds, and adherence.
- Lifestyle: combining medication with a calorie‑controlled diet, physical activity, and behavioral support gives better outcomes.
- Side effects: early nausea or GI effects can lower appetite (contributes to early weight loss) but may limit tolerability.
Is it sustainable?
- Continuing the medication: many people maintain most of their weight loss while on the drug (that’s what trials show).
- Stopping the medication: weight regain is common after stopping unless intensive lifestyle changes or other long‑term treatments are used. Trials and real‑world reports document partial or full regain for many people after discontinuation.
- Therefore, think of GLP‑1s as a long‑term medical treatment for weight management for many people, combined with lifestyle and behavioral care to maintain changes.
Safety and practical considerations
- Common side effects: nausea, vomiting, constipation, diarrhea; usually more pronounced during dose escalation.
- Less common but important: pancreatitis, gallbladder problems, hypoglycemia if used with insulin or sulfonylureas, and theoretical concerns (thyroid C‑cell tumors in animals). Screen and monitor with your clinician.
- Cost/access: these drugs can be expensive, and insurance coverage for weight‑loss indications varies.
- Medical supervision: prescribing and dose escalation should be done by a clinician, with follow‑up for side effects, dosing, and comorbid conditions.
Specific brand notes (why you might consider each)
- Wegovy (semaglutide, Novo Nordisk): FDA‑approved for chronic weight management; strong trial data showing substantial weight loss and a well‑studied safety profile.
- Zepbound (tirzepatide, Eli Lilly) and Mounjaro (tirzepatide for diabetes): tirzepatide has produced larger average weight loss in trials than semaglutide at the doses studied; Zepbound is the weight‑management brand, Mounjaro is the diabetes brand sometimes used off‑label for weight.
- Ozempic (semaglutide, lower doses for diabetes): causes weight loss too but is not the higher-dose Wegovy formulation approved for obesity.
What I recommend you do next
- Talk with a clinician (primary care, endocrinologist) to review your medical history, meds, and goals.
- Consider a coordinated plan: medication + nutrition counseling (registered dietitian) + behavior therapy + physical activity.
- If you want, tell me your current weight and realistic target and I’ll estimate a rough range of expected weight loss over 6–12 months for your situation.
If you want, I can: estimate likely weight loss for your starting weight, compare Wegovy vs Zepbound for your case, or give a sample monitoring checklist to bring to your clinician. Which would you find most helpful?